Latest News

Thursday, 28 July 2016

Early detection of leukaemia patients' resistance to therapy

Adelaide researchers have made a world-first breakthrough in the early detection of patients' resistance to a common treatment for chronic myeloid leukaemia, offering some hope that the patients' treatment could be changed sooner to improve their chances of survival.

The researchers – based in the Cancer Theme at the South Australian Health & Medical Research Institute (SAHMRI) and the University of Adelaide's School of Medicine – have developed a new test that they believe could be adopted by doctors worldwide.

The results of this research are now published online ahead of print in the international journal Leukemia.

Lead author and postdoctoral researcher Dr Laura Eadie says one-in-five chronic myeloid leukaemia (CML) patients are resistant to the leading treatment of their condition.

"The development of the targeted drug Glivec for chronic myeloid leukaemia has been one of the most remarkable success stories in cancer treatment over the past two decades. This is because the drug targets the mutant protein that causes their leukaemia," Dr Eadie says.

"However, about 20% of patients have a poor response to Glivec, and until now we haven't fully understood why. Unfortunately, this means that one-in-five patients could be receiving treatment that ultimately is not benefitting them, losing response to therapy and reducing their chances of survival."

The study looked at the role of P-glycoprotein, a protein that pumps many drugs – including Glivec – out of leukaemia cells.

"Some patients were found to have higher levels of P-glycoprotein in their leukaemic cells after just a few weeks of starting therapy. These patients were much more likely to develop resistance to Glivec later on," Dr Eadie says.

"We've found the greater the increase in P-glycoprotein in patients, the greater their risk is of becoming resistant and not responding to their drug any more, or even succumbing to their disease."

The research team's work shows, for the first time, that assessing a patient's levels of the P-glycoprotein soon after they start receiving Glivec therapy will help to predict that patient’s long-term response to the drug.

"This new test, developed in our laboratory, may provide an opportunity for doctors around the world to change treatment strategies for those patients most at risk of doing poorly on Glivec before they actually lose response to the therapy," Dr Eadie says.

Dr Eadie is also the recipient of a 2016 Fulbright South Australia Postdoctoral Scholarship. Next month, she will travel to the United States to continue research into leukaemia, based at the St. Jude Children’s Research Hospital in Tennessee.

This work will continue her focus on the effectiveness of leukaemia treatments and the mechanisms of resistance in patients.

"I hope that by better understanding the key drivers of response and resistance in patients, these research findings will help to inform clinical practice and ensure the best possible chance of patient survival," she says.

SAHMRI’s Cancer Theme is supported with funding from the Cancer Council’s Beat Cancer Project. Leukaemia Research at SAHMRI is also supported by the Leukaemia Foundation of Australia (LFA) - Dr Laura Eadie was a LFA PhD Scholar.
[Full Story]

RSS News Feed

Latest Headlines

Wednesday, 27 July 2016

NZ wren DNA analysis reshapes geological theory

A DNA analysis of living and extinct species of mysterious New Zealand wrens may change theories around the country's geological and evolutionary past. [Full Story]

Monday, 25 July 2016

New University professorial appointment at Lyell McEwin

Research and medical teaching will be boosted at the Lyell McEwin Hospital with the University of Adelaide's first Chair of Medicine based at the Lyell McEwin Hospital, in a joint appointment with the Northern Adelaide Local Health Network (NALHN). [Full Story]

Thursday, 21 July 2016

Brain probe to examine drug dangers

University of Adelaide researchers have developed a new optical-fibre based probe, which can measure localised temperature-change deep inside the brain. [Full Story]

Thursday, 21 July 2016

Consumers treat superfoods as "extra insurance"

Australian consumers are skeptical about new superfoods but still consume them for a bit of "extra insurance" for their health. [Full Story]

Upcoming Events

Images of Justice Retrospective display self-guided tour

Monday, 25 July 2016 - Friday, 12 August 2016, all day
Ligertwood Building, North Terrace Campus

Chris Herzfeld's Superheroes: Toxic Debris

Thursday, 28 July 2016 - Monday, 31 October 2016
Level 3, The Hub

Elder Hall Evening Concert Series - Schubertiade

Saturday, 30 July 2016, 6:30 pm to 8:45 pm
Elder Hall, University of Adelaide

Launch of new University public sculpture 'Standing Work no. 3'

Thursday, 4 August 2016, 10:30 am to 11:30 am
Goodman Crescent, North Terrace Campus

Walk a mile in my boots

Friday, 5 August 2016, 7:30 am to 9:00 am
Victoria Park on Wakefield Road

Find an Expert

Events Calendar

< July 2016 >
S M T W T F S
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

News Publications

Adelaidean
The Adelaidean provides news about the teaching, research and other activities of the University.

Lumen
The University's bi-annual alumni magazine.

Staff News
The University's weekly newsletter keeping staff informed about what's on.

The Media Unit

For help with finding an expert for your story or the latest news from the University of Adelaide, please contact one of the Media Officers below:

Lachlan Parker
Deputy Director
Media & Corporate Relations
work: +61 8 8313 3196
mobile: +61 417 810 890

David Ellis
Media and Communications Officer
work: +61 8 8313 5414
mobile +61 421 612 762

Robyn Mills
Media and Communications Officer
work: +61 8 8313 6341
mobile +61 410 689 084


top